Seegnal Announces Letter of Intent with U.S.-Based Care Facility, Marking First Penetration of the American Healthcare Market

Commercial milestone marks Seegnal's first engagement in the United States, advancing the Company's commercial expansion strategy; Pilot expected to begin shortly

CALGARY, AB, May 19, 2026 (GLOBE NEWSWIRE) -- Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a developer of innovative healthcare technology focused on mitigating medication risks, today announced that it has entered into a letter of intent (the "LOI"), dated May 5, 2026, with a U.S.-based long-term care provider to conduct a pilot program with Seegnal's clinical decision support platform. The LOI marks Seegnal's first pilot engagement in the United States.

Under the LOI, the parties intend to conduct a pilot program during which Seegnal's platform will analyze prescription data without affecting clinical workflows, with the goal of identifying medication-related risks and optimization opportunities across the resident population. The contemplated pilot is expected to run between 8 and 12 weeks from the receipt of data, followed by a potential extended evaluation period. The pilot program is expected to begin shortly following the execution of the LOI.

Approximately 1.2 million Americans live in CMS-certified nursing facilities,¹ a population characterized by advanced age, multiple chronic conditions, and high rates of polypharmacy. Adverse drug events are a significant and often preventable source of hospitalization in this population: an estimated 99,628 emergency hospitalizations each year in U.S. adults aged 65 and older are attributable to adverse drug events.²

“Long-term care residents are among the most medication-vulnerable populations in U.S. healthcare, typically managing multiple chronic conditions, taking many concurrent prescriptions, and facing elevated risk of adverse drug events that drive avoidable hospitalizations and pharmacy spend," said Elad Bibi-Aviv, Chief Executive Officer of Seegnal. "Entering the U.S. market through long-term care is a deliberate first step. It is a setting where Seegnal's patient-specific approach to medication safety can demonstrate clinical and economic value quickly, and it provides a repeatable entry point for the broader U.S. commercial expansion we have outlined for the Company."

Schreibe Deinen Kommentar